Vaxcyte Inc
PCVX33.075USD
+0.055+0.17%
交易中 （美东）报价延迟15分钟
4.26B总市值
亏损市盈率 TTM
关于 Vaxcyte Inc 公司
Vaxcyte Inc. 是一家临床阶段疫苗公司。该公司致力于开发广谱结合疫苗和蛋白质疫苗，以预防或治疗细菌性传染病。其主要候选疫苗 VAX-24 是一种已进入 III 期临床试验的 24 价载体保留型肺炎球菌结合疫苗 (PCV)，正在开发用于预防侵袭性肺炎球菌疾病 (IPD)。VAX-31 是该公司的下一代 31 价 PCV，用于预防成人 IPD。其产品线还包括 VAX-A1、VAX-PG 和 VAX-GI。VAX-A1 是一种新型结合疫苗候选疫苗，旨在预防由 A 组链球菌 (Group A Strep) 引起的疾病。VAX-PG 是一种新型蛋白质疫苗候选疫苗，针对导致牙周炎（一种慢性口腔炎症疾病）的病原体。VAX-GI 是一种新型临床前疫苗候选疫苗，正在开发用于预防痢疾和志贺氏菌病。其技术平台包括先进的化学和XpressCF无细胞蛋白质合成平台。
公司简介
公司代码PCVX
公司名称Vaxcyte Inc
上市日期Jun 12, 2020
CEOMr. Grant E. Pickering
员工数量414
证券类型Ordinary Share
年结日Jun 12
公司地址825 Industrial Road, Ste. 300
城市SAN CARLOS
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94070
电话16508370111
网址https://vaxcyte.com/
公司代码PCVX
上市日期Jun 12, 2020
CEOMr. Grant E. Pickering
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
676.65K
+3.13%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
83.56K
+6.06%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
34.31K
+21.13%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
3.04K
--
Mr. John P. Furey
Mr. John P. Furey
Independent Director
Independent Director
3.04K
--
Dr. Olivier Brandicourt
Dr. Olivier Brandicourt
Independent Director
Independent Director
1.15K
--
Dr. Heath Lukatch, Ph.D.
Dr. Heath Lukatch, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
676.65K
+3.13%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
83.56K
+6.06%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
34.31K
+21.13%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月2日 周六
更新时间: 8月2日 周六
持股股东
股东类型
持股股东
持股股东
占比
Janus Henderson Investors
11.27%
RA Capital Management, LP
9.45%
The Vanguard Group, Inc.
9.32%
Fidelity Management & Research Company LLC
8.31%
BlackRock Institutional Trust Company, N.A.
7.08%
Other
54.57%
持股股东
持股股东
占比
Janus Henderson Investors
11.27%
RA Capital Management, LP
9.45%
The Vanguard Group, Inc.
9.32%
Fidelity Management & Research Company LLC
8.31%
BlackRock Institutional Trust Company, N.A.
7.08%
Other
54.57%
股东类型
持股股东
占比
Investment Advisor
47.62%
Investment Advisor/Hedge Fund
40.88%
Hedge Fund
12.35%
Venture Capital
10.72%
Research Firm
1.95%
Private Equity
0.97%
Sovereign Wealth Fund
0.85%
Bank and Trust
0.73%
Individual Investor
0.70%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
652
151.34M
117.31%
-374.47K
2025Q1
669
149.26M
115.73%
-5.52M
2024Q4
629
143.44M
111.44%
-3.61M
2024Q3
579
138.80M
114.99%
+5.28M
2024Q2
508
125.57M
113.86%
-5.08M
2024Q1
487
122.06M
113.01%
+8.05M
2023Q4
444
106.09M
111.72%
-6.02M
2023Q3
417
110.70M
121.97%
-7.51M
2023Q2
397
109.13M
122.07%
+11.09M
2023Q1
366
92.70M
119.26%
-1.36M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Janus Henderson Investors
14.54M
11.27%
+2.77M
+23.58%
Apr 30, 2025
RA Capital Management, LP
12.19M
9.45%
+3.50M
+40.28%
Mar 31, 2025
The Vanguard Group, Inc.
12.02M
9.32%
+82.12K
+0.69%
Mar 31, 2025
Fidelity Management & Research Company LLC
10.73M
8.31%
-632.25K
-5.57%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.13M
7.08%
-112.81K
-1.22%
Mar 31, 2025
Wellington Management Company, LLP
6.42M
4.97%
+1.97M
+44.39%
Mar 31, 2025
Capital Research Global Investors
6.11M
4.74%
-100.42K
-1.62%
Mar 31, 2025
State Street Global Advisors (US)
4.41M
3.42%
-131.72K
-2.90%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.44M
2.66%
-429.53K
-11.11%
Mar 31, 2025
Kynam Capital Management LP
3.20M
2.48%
+863.20K
+36.94%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ALPS Medical Breakthroughs ETF
2.84%
Harbor Health Care ETF
2.75%
SPDR S&P Biotech ETF
1.36%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Direxion Daily S&P Biotech Bull 3X Shares
0.77%
Invesco Nasdaq Biotechnology ETF
0.47%
ProShares Ultra Nasdaq Biotechnology
0.47%
iShares Biotechnology ETF
0.42%
Nuveen ESG Small-Cap ETF
0.36%
JPMorgan Fundamental Data Science Small Core ETF
0.36%
查看更多
ALPS Medical Breakthroughs ETF
占比2.84%
Harbor Health Care ETF
占比2.75%
SPDR S&P Biotech ETF
占比1.36%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.85%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.77%
Invesco Nasdaq Biotechnology ETF
占比0.47%
ProShares Ultra Nasdaq Biotechnology
占比0.47%
iShares Biotechnology ETF
占比0.42%
Nuveen ESG Small-Cap ETF
占比0.36%
JPMorgan Fundamental Data Science Small Core ETF
占比0.36%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
